How Has the Rheumatoid Arthritis Drugs Market Size Evolved in Recent Years?
The rheumatoid arthritis drugs market has seen considerable growth due to a variety of factors.
•The market size of drugs for Rheumatoid Arthritis has seen a slight increase in the past few years. It is projected to expand from $60.3 billion in 2024 to $60.71 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 0.7%.
The upward trend during the historic period is believed to be due to a rise in the prevalence of the disease, expansion of the health care infrastructure, initiatives in awareness and education, government support and strategies, and collaborative partnerships.
What are the Market Size and Expected Growth Rates for the Rheumatoid Arthritis Drugs Market?
The rheumatoid arthritis drugs market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations are high for the steady expansion of the rheumatoid arthritis drugs market in the forthcoming years, growing to $66.61 billion by 2029 at a compound annual growth rate (CAGR) of 2.3%.
Trends in personalized medicine, growth of emerging markets, pipeline developments, emphasis on combination therapies, and increased spending in healthcare are all crucial contributors to the prospective growth during the forecast period. The prodigious trends projected to dominate the forecast period encompass dominance of biological therapies, the impact of biosimilars, advancements in personalized medicine, expansion of oral therapies, and an emphasis on early diagnosis and intervention.
Which Key Drivers Are Propelling The Rheumatoid Arthritis Drugs Market's Growth?
As the cases of arthritis continue to escalate, they are anticipated to fuel the expansion of the rheumatoid arthritis drugs market. Rheumatoid arthritis, an autoimmune and inflammatory disease, occurs when the immune system erroneously attacks healthy cells in the body, resulting in painful swelling in the impacted body regions. There are readily accessible medications and self-management techniques to effectively treat rheumatoid arthritis, which not only relieve pain but also improve joint mobility and prevent disease progression. For instance, according to the data released by the National Center for Health Statistics, a US government agency in February 2024, the prevalence of diagnosed arthritis in adults, age-adjusted, was 18.9% in 2022. Women (21.5%) were more prone to arthritis than men (16.1%). Furthermore, the prevalence increased drastically with age, rising from 3.6% in adults aged 18–34 to 53.9% in individuals aged 75 and older. Consequently, the increasing arthritis incidences are likely to spur demand in the rheumatoid arthritis drug market.
What Are The Key Segments Within The Global Rheumatoid Arthritis Drugs Market?
The rheumatoid arthritis drugs market covered in this report is segmented –
1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Response Modifiers (BRMs), Other Drug Types
2) By Route Of Administration: Oral, Parenteral, Topical, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Indomethacin
2) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone
3) By Disease-Modifying Antirheumatic Drugs: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide
4) By Biologic Response Modifiers: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, B-cell Inhibitors
5) By Other Drug Types: Janus Kinase Inhibitors, Other Novel Therapies
Pre-Book The Rheumatoid Arthritis Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Rheumatoid Arthritis Drugs Market?
The trend of product innovation is rapidly gaining momentum in the rheumatoid arthritis drug market. To maintain their market standing, companies within the sector are increasingly focusing on the introduction of new drugs. For example, R-Pharm, a leading high-tech pharmaceutical company based in Russia, released Olokizumab in August 2022. This humanized monoclonal antibody is designed to specifically target the cytokine interleukin-6, a messenger molecule that contributes to joint destruction in rheumatoid arthritis. Additionally, similar to TNF (tumor necrosis factor), it induces inflammatory responses in the body, thereby reducing disease activity in a significant number of rheumatoid arthritis patients.
Who Are the Key Players in the Rheumatoid Arthritis Drugs Market?
Major companies operating in the rheumatoid arthritis drugs market include:
• Pfizer Inc.
• Abbvie Inc.
• Amgen Inc.
• Novartis AG
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• F-Hoffmann La Roche AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Merck & Co Inc.
• Johnson & Johnson Inc.
• Bayer AG
• Teva Pharmaceuticals Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Sanofi S.A
• Biogen Inc.
• Regeneron Pharmaceuticals Inc.
• Galapagos NV
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• Mitsubishi Tanabe Pharma Corporation
• UCB S.A.
• Astellas Pharma Inc.
• Corbus Pharmaceuticals Holdings Inc.
• Roche Holding AG
• Daiichi Sankyo Company Limited
• Mallinckrodt Pharmaceuticals
• Gilead Sciences Inc.
What are the Regional Insights into the Rheumatoid Arthritis Drugs Market?
North America was the largest region in the rheumatoid arthritis drugs market in 2024.North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
